Allison Dorval - Verve Therapeutics CFO Officer
| VERV Stock | USD 7.70 0.45 6.21% |
Insider
Allison Dorval is CFO Officer of Verve Therapeutics
| Age | 48 |
| Phone | 617 603 0070 |
| Web | https://www.vervetx.com |
Allison Dorval Latest Insider Activity
Tracking and analyzing the buying and selling activities of Allison Dorval against Verve Therapeutics stock is an integral part of due diligence when investing in Verve Therapeutics. Allison Dorval insider activity provides valuable insight into whether Verve Therapeutics is net buyers or sellers over its current business cycle. Note, Verve Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Verve Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Allison Dorval over a month ago Disposition of 555 shares by Allison Dorval of Verve Therapeutics at 5.64 subject to Rule 16b-3 |
Verve Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2219) % which means that it has lost $0.2219 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4067) %, meaning that it created substantial loss on money invested by shareholders. Verve Therapeutics' management efficiency ratios could be used to measure how well Verve Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Ann Lee | Prime Medicine, Common | 63 | |
| Bruce Eaton | Editas Medicine | 70 | |
| Thomas Catinazzo | Relay Therapeutics | 49 | |
| Cindy Hayashi | Caribou Biosciences | N/A | |
| Yi Zhou | Adaptive Biotechnologies Corp | N/A | |
| MA MBA | Relay Therapeutics | 48 | |
| Feng Zhang | Editas Medicine | N/A | |
| MBA MBA | Adaptive Biotechnologies Corp | 50 | |
| Alexis Komor | Beam Therapeutics | N/A | |
| Mark Wallet | Century Therapeutics | N/A | |
| Jason MBA | Caribou Biosciences | 56 | |
| Andrew May | Intellia Therapeutics | N/A | |
| George Church | Editas Medicine | 71 | |
| Dr MBA | Blueprint Medicines Corp | 55 | |
| JD MBA | Blueprint Medicines Corp | 51 | |
| Shane Williams | Century Therapeutics | N/A | |
| Lawrence Klein | Crispr Therapeutics AG | 42 | |
| David Liu | Prime Medicine, Common | N/A | |
| Kenneth JD | Century Therapeutics | N/A | |
| Mark Adams | Adaptive Biotechnologies Corp | 57 | |
| Brittany Mccleery | Sana Biotechnology | N/A | |
Management Performance
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.22 |
Verve Therapeutics Leadership Team
Elected by the shareholders, the Verve Therapeutics' board of directors comprises two types of representatives: Verve Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Verve. The board's role is to monitor Verve Therapeutics' management team and ensure that shareholders' interests are well served. Verve Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Verve Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jennifer Robinson, Vice Communications | ||
| Allison CPA, CFO Officer | ||
| Kaitlin Duffy, Executive Resources | ||
| Troy Lister, Chief Officer | ||
| MD MPH, CoFounder Advisor | ||
| Joan MBA, Chief Officer | ||
| FACC MD, CoFounder | ||
| Anthony MD, CoFounder Member | ||
| Allison Dorval, CFO Officer | ||
| Andrew JD, COO President | ||
| Andrew MD, Chief Officer | ||
| Sekar MD, CEO CoFounder | ||
| Margaret Beaudoin, VP Fin | ||
| Issi MBA, CoFounder Advisor | ||
| Burt MD, CoFounder Board |
Verve Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Verve Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (8.29) % | ||||
| Current Valuation | 145.15 M | ||||
| Shares Outstanding | 84.66 M | ||||
| Shares Owned By Insiders | 5.28 % | ||||
| Shares Owned By Institutions | 97.96 % | ||||
| Number Of Shares Shorted | 14.79 M | ||||
| Price To Earning | 5.45 X | ||||
| Price To Book | 1.21 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Verve Stock Analysis
When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.